A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Oral RGT001-075 in Adult Patients With Uncontrollable Type 2 Diabetes Mellitus on Metformin Therapy
Sponsor: Regor Pharmaceuticals Inc.
Terminated
Terminated due to financial constraint.
Other terminated trials from Regor Pharmaceuticals Inc.
More terminations from Regor Pharmaceuticals Inc.
Other Type 2 Diabetes Mellitus trials with similar outcome
Listed as NCT05297045, this PHASE2 trial focuses on Type 2 Diabetes Mellitus and remains terminated or withdrawn. Sponsored by Regor Pharmaceuticals Inc., it has been updated 6 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jun 2022 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Apr 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Mar 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Regor Pharmaceuticals Inc.
For direct contact, visit the study record on ClinicalTrials.gov .